Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, ICU Medical's PEG is 1. ICU Medical's 5-Year TTM EBITDA Growth Rate is 7.51.
ICU Medical's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $3.98. Therefore, the Peter Lynch Fair Value for today is $29.87.
As of today (2024-06-02), ICU Medical's share price is $106.36. ICU Medical's Peter Lynch fair value is $29.87. Therefore, ICU Medical's Price to Peter Lynch Fair Value Ratio for today is 3.56.
The historical rank and industry rank for ICU Medical's Peter Lynch Fair Value or its related term are showing as below:
ICUI'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 2.38 Med: 3.88 Max: 98.43
Current: 3.56
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of ICU Medical was 98.43. The lowest was 2.38. And the median was 3.88.
ICUI's Price-to-Peter-Lynch-Fair-Value is ranked worse than 80.73% of 192
companies
in the Medical Devices & Instruments industry
Industry Median: 1.675
vs ICUI: 3.56
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
ICU Medical Peter Lynch Fair Value Historical Data
The historical data trend for ICU Medical's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ICU Medical's Peter Lynch Fair Value
For the Medical Instruments & Supplies subindustry, ICU Medical's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where ICU Medical's Price-to-Peter-Lynch-Fair-Value falls into.
ICU Medical Peter Lynch Fair Value Calculation
ICU Medical's Peter Lynch Fair Value for today is calculated as
ICU Medical's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.98.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
ICU Medical (NAS:ICUI) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 7.51 instead of 15 in this case.
ICU Medical's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
106.36
/
29.87
=
3.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical Peter Lynch Fair Value Related Terms
Thank you for viewing the detailed overview of ICU Medical's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.
ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017, and Smiths Medical from Smiths Group in 2022. It holds top-tier positions in its original reporting segments: infusion consumables (25% of 2022 revenue), IV solutions (16%), infusion systems (15%), and critical care (2%) as well as its new Smiths segments: Smiths infusion systems (15%), vascular access (14%), and vital care (12%). The combined entity remains primarily U.S. focused, generating over 64% of its sales domestically.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ICUI has been successfully added to your 